Microfluidic-based systems for the management of diabetes

Area of Science:

• Biomedical Engineering
• Medical Devices
• Endocrinology

Background:

• Diabetes affects 500 million globally, with invasive glucose testing and insulin delivery causing patient non-adherence.
• Current diabetes management relies on finger-prick tests and subcutaneous insulin injections, which are painful and inconvenient.
• There is a significant need for improved, less invasive methods for diabetes diagnosis, monitoring, and treatment.

Purpose of the Study:

• To review the role of microfluidic devices in diabetes diagnosis and monitoring.
• To explore microfluidic technologies for the delivery of diabetes medications, including insulin.
• To summarize recent advancements in microfluidic applications for diabetes management.

Main Methods:

• Review of recent literature on microfluidic devices for diabetes.
• Analysis of microfluidic platforms for non-invasive glucose testing (e.g., using other body fluids).
• Examination of microfluidic systems for transdermal, oral, intraperitoneal, and inhalation-based drug delivery (insulin, metformin, GLP-1 agonists).

Main Results:

• Microfluidic devices show promise for non-invasive glucose monitoring and analysis of biomarkers like HbA1c.
• Minimally invasive microneedle arrays and other microfluidic platforms are being developed for insulin delivery.
• While microfluidic glucose sensing is clinically advanced, drug delivery technologies are largely preclinical.

Conclusions:

• Microfluidics offers innovative solutions to overcome the limitations of traditional diabetes management.
• Further research and development are needed to advance microfluidic drug delivery systems to clinical application.
• Microfluidic technologies hold significant potential for improving the quality of life for diabetic patients.